EverHint – Dip Bounce V2 (Reclaim) – Top 15 Signals for Sep 17, 2026
Excerpt: 15 signals (from 35 total). Healthcare leads (25). price range $8-$183. 2 with insider selling.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
The broad market is exhibiting strong bullish momentum on September 17, 2026, with all three major indices posting solid gains led by the Nasdaq's 1.69% advance. This risk-on environment is particularly constructive for dip-bounce reclaim strategies, as rising tide conditions tend to accelerate recovery moves in stocks that had previously pulled back. When the broader market is trending higher with conviction, reclaim setups benefit from the tailwind of improved sentiment, making it easier for price to follow through above key technical levels rather than stalling out.
The VIX dropping sharply to 15.44, a decline of nearly 13%, signals a meaningful compression in implied volatility and a reduction in perceived near-term risk. For intraday swing setups like dip_bounce_v2_reclaim, lower volatility is a double-edged dynamic — while it reduces the likelihood of whipsaw reversals that can stop out positions prematurely, it also narrows the expected intraday range, meaning profit targets may need to be calibrated more conservatively. Traders should expect cleaner, more orderly price action rather than explosive moves.
Healthcare emerging as the top sector for today's signals aligns well with the current market backdrop. Healthcare tends to attract rotation when investors are broadly risk-tolerant but also seeking relative stability within a rally, suggesting the sector is participating in the upside without being purely speculative. This defensive-growth positioning within a rising market can produce reliable follow-through on reclaim setups, as institutional buying tends to be more sustained and less prone to sudden profit-taking compared to more momentum-driven sectors.
📊 Signals (15 of 35 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | CAI | Caris Life Sciences, Inc. | Healthcare | $30.92 | 0.38 | — | $8.7B |
| 2 | GH | Guardant Health, Inc. | Healthcare | $183.10 | 0.31 | Sell -$632,193 | $24.6B |
| 3 | TEM | Tempus AI, Inc. | Healthcare | $80.36 | 0.26 | — | $14.1B |
| 4 | TGTX | TG Therapeutics, Inc. | Healthcare | $56.47 | 0.24 | — | $8.6B |
| 5 | MRNA | Moderna, Inc. | Healthcare | $158.07 | 0.22 | — | $62.7B |
| 6 | PGEN | Precigen, Inc. | Healthcare | $7.87 | 0.18 | — | $2.8B |
| 7 | ADPT | Adaptive Biotechnologi... | Healthcare | $28.55 | 0.17 | — | $4.6B |
| 8 | ARE | Alexandria Real Estate... | Real Estate | $56.34 | 0.16 | — | $9.8B |
| 9 | CSTL | Castle Biosciences, Inc. | Healthcare | $36.78 | 0.15 | — | $1.1B |
| 10 | ABCL | AbCellera Biologics Inc. | Healthcare | $12.73 | 0.14 | — | $3.9B |
| 11 | DHC | Diversified Healthcare... | Real Estate | $8.13 | 0.14 | — | $2.0B |
| 12 | BWIN | The Baldwin Insurance ... | Financial Services | $31.95 | 0.14 | — | $2.6B |
| 13 | BRKR | Bruker Corporation | Healthcare | $63.05 | 0.14 | — | $9.6B |
| 14 | INDV | Indivior Pharmaceutica... | Healthcare | $35.69 | 0.14 | — | $4.5B |
| 15 | HAE | Haemonetics Corporation | Healthcare | $107.60 | 0.14 | — | $4.9B |
Field Notes
Sector concentration: Healthcare (25), Real Estate (4), Basic Materials (2)
Insider selling (7d): GH (Guardant Health, Inc., -$632,193)
Data coverage: 5.7% insider (7d), 0.0% congressional (30d), 0.0% earnings, 25.7% news (7d)
Peer Analysis
DHC (Diversified Healthcare Trust): Leads 5 peers: HPP ($11.60), PDM ($9.36), CSR ($56.84), MFA ($8.50), PMT ($8.94)
Recent Headlines
ADPT (Adaptive Biotechnologies Corporation)
- Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
BWIN (The Baldwin Insurance Group, Inc.)
- Baldwin Group Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of The Baldwin Group, Inc. - BWIN
- Baldwin Group Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of The Baldwin Group, Inc. - BWIN
CAI (Caris Life Sciences, Inc.)
- Caris Life Sciences: Diagnostics Growth With Room To Run
MRNA (Moderna, Inc.)
- Moderna Stock Is Surging: What's Going On?
- Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
- Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
- Why is Moderna stock surging today?
TEM (Tempus AI, Inc.)
- Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (25 signals) suggests sector-specific rotation.
Trading tips for this strategy:
- Entry timing: Consider entering on next-day weakness or at previous day's close level
- Position sizing: Start small (1-2% of portfolio per signal)
- Stop loss: Below today's low (tight stops for mean reversion)
- Take profit: 3-5% bounce target, or previous day's high
- Time stop: Exit if no bounce in 1-3 days
Risk warning: Mean reversion can fail in strong downtrends - check broader market context
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.